{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=3", "query": { "intervention": "Phase 1b", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2479, "total_pages": 248, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T02:11:36.379Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03065335", "title": "Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer", "Major Depressive Disorder", "Depression" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cobot TS MV robotic arm for TMS", "type": "DEVICE" }, { "name": "NeurOptics PLRTM-30000 Pupillometer", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2017-05-25", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03065335" }, { "nct_id": "NCT05648110", "title": "Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19, SARS-CoV-2" ], "interventions": [ { "name": "AZD5156 (Parent study Sentinel Safety Cohort)", "type": "BIOLOGICAL" }, { "name": "Placebo (Parent study Sentinel Safety Cohort)", "type": "BIOLOGICAL" }, { "name": "EVUSHELD™ (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "AZD3152 (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "Placebo (Parent study Main Cohort)", "type": "BIOLOGICAL" }, { "name": "AZD3152 (Sub-study)", "type": "BIOLOGICAL" }, { "name": "AZD7442 - EVUSHELD™ (Sub-study)", "type": "BIOLOGICAL" }, { "name": "AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "12 Years to 130 Years" }, "enrollment_count": 3882, "start_date": "2022-12-16", "completion_date": "2025-02-11", "has_results": true, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 130, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05648110" }, { "nct_id": "NCT07205718", "title": "A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "TAK-188", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 273, "start_date": "2025-11-19", "completion_date": "2029-12-21", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 15, "location_summary": "Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07205718" }, { "nct_id": "NCT02365766", "title": "Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Consolidative Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Jason R. Brown", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2015-05-27", "completion_date": "2024-02-23", "has_results": true, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 9, "location_summary": "Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365766" }, { "nct_id": "NCT02723539", "title": "A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetic Foot Infection" ], "interventions": [ { "name": "MBN-101", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Microbion Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 52, "start_date": "2017-03-06", "completion_date": "2019-07-26", "has_results": false, "last_update_posted_date": "2020-07-02", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 2, "location_summary": "Fresno, California • McAllen, Texas", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "McAllen", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02723539" }, { "nct_id": "NCT03595059", "title": "A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ABBV-155", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2018-07-13", "completion_date": "2025-09-12", "has_results": false, "last_update_posted_date": "2025-12-10", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03595059" }, { "nct_id": "NCT03511196", "title": "Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer", "Stage IV Prostate Cancer", "Advanced Prostate Cancer", "Adenocarcinoma of the Prostate" ], "interventions": [ { "name": "Adaptive Androgen Deprivation Therapy (ADT)", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 17, "start_date": "2018-09-17", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03511196" }, { "nct_id": "NCT05243641", "title": "Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Capmatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2022-08-18", "completion_date": "2024-11-19", "has_results": true, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05243641" }, { "nct_id": "NCT02203773", "title": "Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelogenous Leukemia", "Treatment Naive AML" ], "interventions": [ { "name": "Posaconazole", "type": "DRUG" }, { "name": "ABT-199", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 212, "start_date": "2014-10-06", "completion_date": "2022-06-16", "has_results": false, "last_update_posted_date": "2023-05-16", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 13, "location_summary": "Duarte, California • Sacramento, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02203773" }, { "nct_id": "NCT04854746", "title": "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Norovirus Infections" ], "interventions": [ { "name": "VXA-GI.1.NN", "type": "BIOLOGICAL" }, { "name": "Placebo Tablet", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vaxart", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "55 Years to 80 Years" }, "enrollment_count": 66, "start_date": "2021-04-26", "completion_date": "2022-01-04", "has_results": false, "last_update_posted_date": "2023-02-13", "last_synced_at": "2026-10-19T02:11:36.379Z", "location_count": 3, "location_summary": "Cypress, California • New Orleans, Louisiana • Austin, Texas", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04854746" } ] }